Evidence map›Paper›PMID 27196139›Full record

Observational studyPloS one2016

Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.

Erik J van Helden, Otto S Hoekstra, Ronald Boellaard, Chantal Roth, Emma R Mulder, Henk M W Verheul, C Willemien Menke-van der Houven van Oordt

Registry-linked trialOpen access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01691391 (Treatment Optimization of Anti-EGFR Therapy), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01691391 completednot on this map

Treatment Optimization of Anti-EGFR Therapy (Cetuximab and Panitumumab) in Patients With Metastatic Colorectal Cancer Based Early 18F-FDG-PET

TypeobservationalSponsorAmsterdam UMC, location VUmcRan2012 to 2020Enrolled46ConditionsColorectal CancerArms(Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-PointJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Erik J van HeldenVUmc Cancer Center Amsterdam, VU University medical center, Department of Medical Oncology, Amsterdam, the Netherlands.
Otto S HoekstraDepartment of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.
Ronald BoellaardDepartment of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.
Chantal RothVUmc Cancer Center Amsterdam, VU University medical center, Department of Medical Oncology, Amsterdam, the Netherlands.
Emma R MulderDepartment of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.
Henk M W VerheulVUmc Cancer Center Amsterdam, VU University medical center, Department of Medical Oncology, Amsterdam, the Netherlands.
C Willemien Menke-van der Houven van OordtVUmc Cancer Center Amsterdam, VU University medical center, Department of Medical Oncology, Amsterdam, the Netherlands.ORCID 0000-0002-5404-5883
Amsterdam UMC Location Vrije Universiteit Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this pilot study was to explore intrapatient mixed metabolic response and early 18F-FDG PET response evaluation using predefined quantification strategies in patients with advanced KRAS wild-type colorectal adenocarcinoma (mCRC) treated with cetuximab.

methodsA 18F-FDG PET was performed at baseline and after 2 cycles of cetuximab. Metabolic response was categorized using thresholds suggested in PERCIST. Quantitative analysis was done for the sum of all target lesions, ≤ 5 lesions and the metabolically most active lesion per PET. Quantitative data were correlated with clinical benefit, according to RECIST v1.1, after two months of treatment.

resultsIn nine evaluable patients the total number of target lesions was 34 (1-8 per patient). Mixed metabolic response was observed in three out of seven patients with multiple target lesions, using TLG. Dichotomised metabolic data of the sum of all or ≤ 5 lesions had a concordance with clinical benefit of 89% using SULmax or SULpeak, and 100% using TLG. Evaluating the metabolically most active lesion, concordance was 89% for all three units. Additionally, the decrease in TLG was significantly correlated with PFS for all three quantification strategies.

conclusionMixed metabolic response was observed in nearly half of the patients with advanced KRAS wild-type mCRC treated with cetuximab. If ≤ 5 target lesions were evaluated using TLG clinical benefit was predicted correctly for all patients. Moreover, decrease in TLG is significantly correlated with the duration of PFS. Validation of these promising preliminary results in a larger cohort is currently on-going.

trial registrationClinicalTrials.gov NCT01691391.

Indexed as

AdenocarcinomaAgedAlgorithmsAntineoplastic AgentsBiomarkersCetuximabColorectal NeoplasmsErbB ReceptorsFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedMultimodal ImagingNeoplasm MetastasisPilot ProjectsAntineoplastic AgentsBiomarkersCetuximabEGFR protein, humanErbB ReceptorsFluorodeoxyglucose F18KRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID27196139
PMCPMC4873260
OpenAlexW2399067351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.